But researchers warn that there is no real evidence that it actually works.doi:10.1038/nature.2016.19756Heidi LedfordNature
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon ...
Last week, the FDAapproved Gilead Science’s Sunlenca(lenacapavir), the first and only capsid inhibitor-based HIV treatment. The treatment is intended for adult patients whose HIV cannot be treated with other available drugs because of resistance, tolerance, or safety considerations. Sunl...
Up to 15 percent of people living with ALS are thought to have a genetic form of the disease, whether or not they have a known family history. As genetic testing is not broadly available, Biogen sponsors a genetic testing program, ALS Identified™, for people living with ALS and their f...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Trodelvy ® for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on
(RTTNews) - The U.S. Food and Drug Administration approved the supplemental Biologics License Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with d
1“If approved, Dato-DXd could become the first TROP2-directed antibody-drug conjugate [ADC] for lung cancer, providing a promising option for patients.” With this, the decision from the FDA is expected by July 12, 2025, under the Prescription Drug User Fee Act.1 Dato-DXd is a TROP2...
About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the di...
symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's. As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research and ...
The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T cell treatment available to all providers when their patients need it. Amgen is advancing more than a dozen BiTE molecu...